open access
Interferon lambda with remdesivir as a potential treatment option in COVID-19
Affiliations- Department of Obstetrics and Gynecology, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, Saudi Arabia
- Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
- 1st Department of Cardiology, Medical University of Warsaw, Poland
- Wroclaw Medical University · Department of Emergency Medical Service, Parkowa Str 34, 50-365 Wroclaw, Poland
- Chair and Department of Medical Education, Poznan University of Medical Sciences, Poznan, Poland
- Research Institute in Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Canada
- Cellular and Molecular Research Center, Department of Anatomy, Faculty of Medicine, Iran University of Medical Sciences, Tehran
- 1st Department of Cardiology, Medical University of Gdansk, Poland
open access
Abstract
Abstract
Keywords
remdesivir, interferon lambda, COVID-19, SARS-CoV-2, treatment
About this articleTitle
Interferon lambda with remdesivir as a potential treatment option in COVID-19
Journal
Disaster and Emergency Medicine Journal
Issue
Article type
Letter to the Editor
Pages
174
Published online
2020-06-15
Page views
591
Article views/downloads
1186
DOI
Bibliographic record
Disaster Emerg Med J 2020;5(3):174.
Keywords
remdesivir
interferon lambda
COVID-19
SARS-CoV-2
treatment
Authors
Ishag Adam
Lukasz Szarpak
Krzysztof Jerzy Filipiak
Jacek Smereka
Marek Dabrowski
Saeid Ghavami
Milosz Jaguszewski
References (5)- Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 [Epub ahead of print].
- Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020; 40(1): 68–76.
- Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020; 295(20): 6785–6797.
- Hemann EA, Schwerk J, Savan R. IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol. 2017; 18(10): 1061–1062.
- Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010; 84(11): 5670–5677.